<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MICONAZOLE NITRATE</span><br/>(mi-kon'a-zole)<br/><span class="topboxtradename">Monistat-Derm, </span><span class="topboxtradename">Monistat 3, </span><span class="topboxtradename">Monistat 7, </span><span class="topboxtradename">Femizol-M, </span><span class="topboxtradename">M-Zole, </span><span class="topboxtradename">Micatin, </span><span class="topboxtradename">Tetterine, </span><span class="topboxtradename">Fungoid, </span><span class="topboxtradename">Lotrimin AF, </span><span class="topboxtradename">Desenex<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antifungal</span><br/><b>Prototype: </b>Fluconazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg vaginal suppositories; 2% cream; 2% ointment; 2% powder; 2% spray; 2% solution</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum agent with fungicidal activity. Mode of action is unclear but appears to inhibit uptake of components essential
         for cell reproduction and growth as well as cell wall structure, thus promoting cell death of fungi.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Candida albicans</i> and other species of this genus. Inhibits growth of common dermatophytes <i>Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum,</i> and the organism responsible for tinea versicolor <i>(Malassezia furfur)</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Vulvovaginal candidiasis, tinea pedis (athlete's foot), tinea cruris, tinea corporis, and tinea versicolor caused by dermatophytes.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to miconazole.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Fungal Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply cream sparingly to affected areas twice a day, and once daily for tinea versicolor, for 2 wk (improvement expected in
               23 d, tinea pedis is treated for 1 mo to prevent recurrence) <span class="rdroute">Intravaginal</span> Insert suppository or vaginal cream q h.s. times 7 d (100 mg) or 3 d (200 mg)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply cream sparingly to intertriginous areas (between skin folds) to avoid maceration of skin.</li>
<li>Massage affected area gently until cream disappears.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Urogenital:</span> Vulvovaginal burning, itching, or irritation; maceration, allergic contact dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> may increase INR with <b>warfarin;</b> may inactivate <b>nonoxynol-9</b> spermicides. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Small amount absorbed from vagina. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 2.124 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Expect clinical improvement from topical application in 1 or 2 wk. If no improvement in 4 wk, diagnosis is reevaluated. Treat
            tinea pedis infection for 1 mo to assure permanent recovery.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Complete full course of treatment to ensure recovery.</li>
<li>Do not interrupt vaginal application during menstrual period.</li>
<li>Avoid contact of drug with eyes.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>